There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardelyx (ARDX – Research Report), Community Health (CYH – Research Report) and Artelo Biosciences (ARTL – Research Report) with bullish sentiments.
Ardelyx (ARDX)
Citi analyst Yigal Nochomovitz reiterated a Buy rating on Ardelyx today and set a price target of $7.00. The company’s shares closed last Wednesday at $3.91.
According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ardelyx with a $9.70 average price target, implying a 147.4% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $10.50 price target.
See the top stocks recommended by analysts >>
Community Health (CYH)
Citi analyst Jason Cassorla maintained a Buy rating on Community Health today and set a price target of $7.00. The company’s shares closed last Wednesday at $2.70, close to its 52-week low of $1.88.
According to TipRanks.com, Cassorla ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Community Health with a $5.75 average price target.
Artelo Biosciences (ARTL)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Artelo Biosciences on October 17 and set a price target of $5.00. The company’s shares closed last Wednesday at $1.43, close to its 52-week low of $1.34.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Currently, the analyst consensus on Artelo Biosciences is a Strong Buy with an average price target of $18.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARDX:
- Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
- Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
- Ardelyx announces FDA approves XPHOZAH in adults with CKD
- FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
- Ardelyx trading halted, news pending
